Edgewise Therapeutics Inc
Company Profile
Business description
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company’s product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.
Contact
1715 38th Street
BoulderCO80301
USAT: +1 720 262-7002
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
117
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,723.50 | 17.90 | -0.20% |
| CAC 40 | 7,597.16 | 43.71 | 0.58% |
| DAX 40 | 23,257.40 | 200.02 | 0.87% |
| Dow JONES (US) | 42,171.66 | 44.14 | -0.10% |
| FTSE 100 | 8,829.24 | 37.44 | 0.43% |
| HKSE | 23,530.48 | 292.74 | 1.26% |
| NASDAQ | 19,546.27 | 25.18 | 0.13% |
| Nikkei 225 | 38,403.23 | 85.11 | -0.22% |
| NZX 50 Index | 12,569.05 | 58.27 | -0.46% |
| S&P 500 | 5,980.87 | 1.85 | -0.03% |
| S&P/ASX 200 | 8,505.50 | 18.20 | -0.21% |
| SSE Composite Index | 3,359.90 | 2.21 | -0.07% |